Fig. 3.

Upregulation of IgM⁺- and IgD⁺-expressing CD19⁺B220⁺CD5⁺CD1d⁺ and CD19^-B220⁺CD5⁺CD1d^- Bregs in the livers of HCC/CaMIN mice.

(A–D) Frequencies of (A) IgM⁺IgD^--, (B) IgM⁺IgD⁺-, (C), IgA^-IgD⁺-, and (D) IgA⁺IgD^--expressing CD19⁺B220⁺CD5⁺CD1d⁺ Bregs. (E–H) Frequencies of (E) IgM⁺IgD^--, (F) IgM⁺IgD⁺-, (G) IgA^-IgD⁺-, and (H) IgA⁺IgD^--expressing CD19^-B220⁺CD5⁺CD1d^- Bregs. (I–L) Percentage of (I) IgM⁺IgD^-, (J) IgM⁺IgD⁺, (K), IgA^-IgD⁺, and (L) IgA⁺IgD^- among CD19⁺B220⁺CD5⁺CD1d⁺ Bregs. (M–P) Percentage of (M) IgM⁺IgD^-, (N) IgM⁺IgD⁺, (O), IgA^-IgD⁺, and (P) IgA⁺IgD^- among CD19^-B220⁺CD5⁺CD1d^- Bregs. (Q–T) ELISA to determine the levels of (Q) IgM, (R) IgG, (S) IgA and (T) IgD in the plasma samples of mice with MASLD and HCC/CaMIN. The data were analyzed using the unpaired Student’s t test. The data are shown as the mean ± SEM, n = 6. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001, ∗∗∗∗p <0.0001. Fig. S3 shows the MASLD and HCC/NRAS^G12V/p19^Arf-/- models. Bregs, B regulatory cells; HCC, hepatocellular carcinoma; MASLD, metabolic dysfunction-associated steatotic liver disease.